section name header

Pronunciation

GLIP-i-zide

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: sulfonylureas

Indications

BEERS REMS, High Alert


Action

  • Lowers blood sugar by stimulating the release of insulin from the pancreas and increasing the sensitivity to insulin at receptor sites.
  • May also decrease hepatic glucose production.
Therapeutic effects:
  • Lowering of blood sugar in diabetic patients.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 99%.

Metabolism/Excretion: Mostly metabolized by the liver.

Half-Life: 2.1–2.6 hr.

Time/Action Profile

(hypoglycemic activity)

ROUTEONSETPEAKDURATION
PO15–30 min1–2 hrup to 24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: photosensitivity, rash

Endo: hypoglycemia

F and E: hyponatremia

GI: constipation, cramps, diarrhea, dyspepsia, hepatitis, nausea, vomiting

Hemat: agranulocytosis, APLASTIC ANEMIA, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia

Metab: appetite

Neuro: dizziness, drowsiness, headache, weakness

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Glucotrol, Glucotrol XL